Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)
10 de junio de 2015 actualizado por: AbbVie (prior sponsor, Abbott)
Safety and Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis in Routine Clinical Practice
The research question explored in this study was whether the effectiveness and safety of adalimumab in participants with ankylosing spondylitis was maintained during long-term therapy in routine clinical practice in Germany.
Descripción general del estudio
Estado
Terminado
Condiciones
Descripción detallada
This was a postmarketing observational study (PMOS) for participants with insufficiently controlled, moderate to severe, active AS who were eligible for adalimumab therapy.
Participants started treatment with adalimumab under normal clinical settings in Germany.
Enrolled participants were followed during adalimumab therapy .
Participants were assessed during regular clinic visits for up to 24 months and 359 clinicians (rheumatologists/orthopedists/general practitioners/internist) participated in the study.
Since this was an observational trial, not all doctors followed the stated age limitations and some participants under the age of 18 were enrolled.
Tipo de estudio
De observación
Inscripción (Actual)
4681
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra no probabilística
Población de estudio
Participants with AS in routine clinical practice.
Descripción
Inclusion Criteria:
- Participants with active, AS for at least 4 weeks (BASDAI greater than or equal to 4).
- Participants who failed treatment with two non-steroidal anti-inflammatory drugs (NSAIDs).
- No contraindications for anti-tumor necrosis factors (TNF) therapy.
Exclusion Criteria:
1. Participants who do not meet the above listed inclusion criteria.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Solo caso
- Perspectivas temporales: Futuro
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Ankylosing spondylitis
Participants with ankylosing spondylitis
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The BASDAI was a six question, participant-reported measure of overall disease activity that probed the level of fatigue, neck/back/hip pain, peripheral joint swelling and pain, localized tenderness, as well as morning stiffness severity and duration.
It was scored on a numerical rating scale that ranged from 0 (no symptoms) to 10 (severe symptoms), and the minimum clinically important difference (MCID) was 1.0.
The final BASDAI score was calculated using the following equation, in which 01 - 06 represents the question number: (BASDAI01 + BASDAI02 + BASDAI03 + BASDAI04 + BASDAI05/2 + BASDAI06*1.25/2)/5.
The scale for question 6 was reduced to 0-8 since BASDAI06 was multiplied by 1.25.
Data are reported as the mean change total score from baseline (Month 0).
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The BASFI was a ten question, participant-reported measure that evaluated physical function.
Each question was scored on a numerical rating scale that ranged from 0 (no functional impairment) to 10 (maximal impairment), and the MCID was 0.7.
The mean of the ten questions was the total BASFI score.
Data are reported as the mean change of total score from baseline (Month 0).
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Number of Participants With Drug-Related Adverse Events (AEs)
Periodo de tiempo: From signing of informed consent up to 24 months
|
An adverse event/adverse experience was any reaction, side effect or other untoward event associated with the use of a drug in humans, whether or not the event was considered drug related.
This included adverse events occurring from accidental or deliberate drug overdose, from drug abuse, or from drug withdrawal.
Exacerbations of pre-existing conditions are also considered adverse events.
Data presented are adverse events that are drug-related and are detailed in the adverse event section of this report.
|
From signing of informed consent up to 24 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mean Number of Involved Peripheral Joints
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Peripheral joints were assessed by Tender Joint Counts (TJC) and Swollen Joint Counts (SJC), using pressure and joint manipulation during physical examination.
Seventy-eight TJC and 76 SJC were evaluated and a score of 0 (not tender or swollen) or 1 (tender or swollen) was assigned for each joint with a higher total score indicating a greater number of involved joints.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants With Extraspinal Manifestations
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Extraspinal manifestations (enthesitis, dactylitis, uveitis, psoriasis, and Inflammatory Bowel Disease (IBD)) were assessed by investigators and reported on the basis of their clinical evaluation and participant records.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Erythrocyte Sedimentation Rate (ESR)
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Plasma concentrations of ESR were assessed as a marker of systemic inflammation that provided insights into the overall anti-inflammatory effect of rheumatologic therapies.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Plasma Concentrations of C-Reactive Protein (CRP)
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Plasma concentrations of CRP were assessed as a marker of systemic inflammation that provided insights into the overall anti-inflammatory effect of rheumatologic therapies.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Bath Ankylosing Spondylitis-Global (BAS-G) Score
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The BAS-G was a participant-reported instrument with two items.
In the first item, the participant rated the effect of their disease over the last week, and in the second item, the participant rated the effect of their disease over the previous 6 months.
Each item of the BAS-G was scored on a scale ranging from 0 (no effect) to 10 (very severe effect).
The mean of the two scores was the total BAS-G score and the MCID was 1.5.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Global Assessment of Disease Activity Score
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Global Assessment of Disease Activity was a participant-reported measure that evaluated disease activity.
It was scored on a scale that ranged from 0 to 10; lower scores indicated better patient status.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Participant Fatigue Score
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Using the BASDAI questionnaire, participants assessed the overall level of fatigue/tiredness experienced by him/her.
It was scored on a numerical rating scale from 0 (no symptoms) to 10 (severe symptoms).
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Participant Pain Score
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Using the BASDAI questionnaire, participants assessed the overall level of AS neck, back or hip pain experienced by him/her.
It was scored on a numerical rating scale from 0 (no symptoms) to 10 (severe symptoms).
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants With Morning Stiffness
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Morning stiffness was a participant-reported assessment.
The number of participants with morning stiffness were assessed at each visit.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Duration of Morning Stiffness
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Participants accessed the duration of morning stiffness in 15 minute intervals from 0 to 2 hours.
Data are reported as the mean duration of morning stiffness ± standard deviation.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS) Improvement Criteria
Periodo de tiempo: At 3, 6, 9, 12, 18, and 24 months
|
This is a four domain (participant global assessment of disease activity, assessment of spinal pain, assessment of function (BASFI), and assessment of duration/severity of morning stiffness (mean of BASDAI questions 5 and 6)), participant-reported assessment scored on a scale from 0 (best) to 10 (worst).
To qualify for a 20% improvement, participants were required to have an improvement of greater than or equal to 20% and greater than or equal to 1 unit in at least 3 domains, and no worsening of greater than or equal to 20% and greater than or equal to 1 unit in the remaining domain.
To achieve a 40% improvement, participants were required to have an improvement of greater than or equal to 40% and greater than or equal to 2 units in at least 3 domains, and no worsening at all in the remaining domain.
|
At 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants Achieving ASAS Partial Remission Criteria
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
This is a four domain (participant global assessment of disease activity, assessment of spinal pain, assessment of function (BASFI), and assessment of duration/severity of morning stiffness (mean of BASDAI questions 5 and 6)), participant-reported assessment scored on a scale from 0 (best) to 10 (worst).
To qualify for a partial remission, participants had to have values of 2 or less (on a scale of 10) in each of the 4 domains.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants With Impairment in Daily Activities During the Last 4 Weeks
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The impairment of daily activities was based on participant recall of events that occurred over the 4 weeks before the visit.
Percentage of participants with impairment for 0, less than 7, 7 to 14, and greater than 14 days was assessed.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Percentage of Participants Who Missed Work Days Due to Ankylosing Spondylitis (AS) in the Previous 12 Months
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Mean Missed Work Days Due to Ankylosing Spondylitis in the Previous 12 Months
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Percentage of Participants With In-Patient Hospitalization Due to Ankylosing Spondylitis in the Previous 12 Months
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Mean Days of In-Patient Hospitalization Due to Ankylosing Spondylitis in the Previous 12 Months
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Percentage of Participants on Adalimumab Monotherapy
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Percentage of Participants With Concomitant Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
|
Percentage of Participants With Concomitant Pain Relief/Anti-Inflammatory Agents
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Participants with concomitant pain relief/anti-inflammatory agents like analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, and systemic glucocorticoids were assessed during the study period.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
|
Mean Equivalent Dose of Prednisolone
Periodo de tiempo: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
The mean equivalent dose of prednisolone was calculated based on the International Standard for comparison of different glucocorticoid products.
|
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Director de estudio: Bianca Wittig, MD, AbbVie Deutschland GmbH & Co. KG, Medical Department
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Enlaces Útiles
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de enero de 2006
Finalización primaria (Actual)
1 de mayo de 2014
Finalización del estudio (Actual)
1 de mayo de 2014
Fechas de registro del estudio
Enviado por primera vez
1 de marzo de 2010
Primero enviado que cumplió con los criterios de control de calidad
2 de marzo de 2010
Publicado por primera vez (Estimar)
3 de marzo de 2010
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
9 de julio de 2015
Última actualización enviada que cumplió con los criterios de control de calidad
10 de junio de 2015
Última verificación
1 de junio de 2015
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- P10-147
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .